Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Stock Information for Akari Therapeutics Plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Akari Therapeutics Plc

Akari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant Tumors
Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
Akari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026
Akari Therapeutics Announces ADS Ratio Change
Akari Therapeutics Releases CEO Corner Highlighting Strategic Progress and Path to Clinical Development Under CEO Abizer Gaslightwala
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.